Cover Image

Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC

Head and neck squamous cell carcinoma (HNSCC) patients frequently develop treatment resistance to cetuximab, a monoclonal antibody against EGFR, as well as radiotherapy. Here we addressed extracellular signal-regulated kinase 1/2 (ERK1/2) regulation by cetuximab or fractionated irradiation (IR) and...

Full description

Saved in:
Bibliographic Details
Main Authors: Rong, Chao (Author) , Muller, Marie France (Author) , Xiang, Fang (Author) , Jensen, Alexandra (Author) , Weichert, Wilko (Author) , Major, Gerald (Author) , Plinkert, Peter K. (Author) , Heß, Jochen (Author) , Affolter, Annette (Author)
Format: Article (Journal)
Language:English
Published: 19 May 2020
In: British journal of cancer
Year: 2020, Volume: 123, Issue: 2, Pages: 288-297
ISSN:1532-1827
DOI:10.1038/s41416-020-0892-9
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41416-020-0892-9
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41416-020-0892-9
Get full text
Author Notes:Chao Rong, Marie F. Muller, Fang Xiang, Alexandra Jensen, Wilko Weichert, Gerald Major, Peter K. Plinkert, Jochen Hess and Annette Affolter
Description
Summary:Head and neck squamous cell carcinoma (HNSCC) patients frequently develop treatment resistance to cetuximab, a monoclonal antibody against EGFR, as well as radiotherapy. Here we addressed extracellular signal-regulated kinase 1/2 (ERK1/2) regulation by cetuximab or fractionated irradiation (IR) and conducted in silico prognostic evaluation of the EGFR-MAPK axis in HNSCC.
Item Description:Gesehen am 25.11.2021
Physical Description:Online Resource
ISSN:1532-1827
DOI:10.1038/s41416-020-0892-9

Similar Items